Elon Musk's Neuralink gets U.S. FDA approval for human clinical study of brain implants
Neuralink added that the company is not yet open for a clinical trial.
Top Stories
-
UN Security Council to vote Friday on Palestinian UN membership
-
IMF, World Bank cite significant progress in debt restructuring
-
Germany sending more anti-air missiles to Ukraine helps
-
Gun-shy Australia, reeling from knife crime, weighs security
-
UN committee unable to agree on Palestinian bid for membership
May 25 (Reuters) - Elon Musk's brain-implant company Neuralink on Thursday said it had received U.S. Food and Drug Administration's (FDA) approval to launch first-in-human clinical study.
Several times since 2019, billionaire Elon Musk has predicted his brain-chip company would soon secure FDA approval for human trials. But the company's application was rejected in early 2022, and the company was working through the agency's concerns over the safety of the experimental implant.
"This is the result of incredible work by the Neuralink team in close collaboration with the FDA and represents an important first step that will one day allow our technology to help many people," Neuralink said in a tweet on Thursday.
Neuralink added that the company is not yet open for a clinical trial.
Neuralink is developing a brain implant it hopes will help paralyzed people walk again and cure other neurological ailments.
U.S. FDA did not immediately respond to Reuters request for comment.
